Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Blueprint Medicines Corporation patents


Recent patent applications related to Blueprint Medicines Corporation. Blueprint Medicines Corporation is listed as an Agent/Assignee. Note: Blueprint Medicines Corporation may have other listings under different names/spellings. We're not affiliated with Blueprint Medicines Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Blueprint Medicines Corporation-related inventors


Compounds useful for treating disorders related to ret

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Compounds useful for treating disorders related to ret

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Prkacb fusions

The invention provides PRKACB gene fusions, PRKACB fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated wiih PRKACB fusions, such as conditions mediated by aberrant PRKACB expression or activity or overexpression of PRKACB.... Blueprint Medicines Corporation

Inhibitors of activin receptor-like kinase

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Inhibitors of ret

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Inhibitors of the fibroblast growth factor receptor

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.... Blueprint Medicines Corporation

Prkc fusions

The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.... Blueprint Medicines Corporation

Fgr fusions

FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.... Blueprint Medicines Corporation

Compositions useful for treating disorders related to kit

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.... Blueprint Medicines Corporation

Tert fusions

The invention provides TERT gene fusions, TERT fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing diseases or disorders associated with TERT fusions, such as conditions mediated by aberrant TERT expression or activity, or overexpression of TERT.... Blueprint Medicines Corporation

Inhibitors of the fibroblast growth factor receptor

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Compounds and compositions useful for treating disorders related to ntrk

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.... Blueprint Medicines Corporation

Raf1 fusions

The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.... Blueprint Medicines Corporation

Inhibitors of ret

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.... Blueprint Medicines Corporation

Pkn1 fusions

The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.... Blueprint Medicines Corporation

Compounds and compositions useful for treating disorders related to ntrk

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.... Blueprint Medicines Corporation

Inhibitors of the fibroblast growth factor receptor

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.... Blueprint Medicines Corporation

Compositions useful for treating disorders related to kit

Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.... Blueprint Medicines Corporation

Met fusions

The invention provides MET gene fusions. MET fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with MET fusions, such as conditions mediated by aberrant MET expression or activity or overexpression of MET.... Blueprint Medicines Corporation

Pik3ca fusions

The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.... Blueprint Medicines Corporation

Compositions useful for treating disorders related to kit

Compounds and compositions useful for treating disorders related to Kit are described herein.... Blueprint Medicines Corporation

Compositions useful for treating disorders related to kit and pdfgr

Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.... Blueprint Medicines Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Blueprint Medicines Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Blueprint Medicines Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###